PT  - JOURNAL ARTICLE
AU  - Rahbar, Kambiz
AU  - Essler, Markus
AU  - Pabst, Kim M.
AU  - Eiber, Matthias
AU  - Fougère, Christian la
AU  - Prasad, Vikas
AU  - Rassek, Philipp
AU  - Hasa, Ergela
AU  - Dittmann, Helmut
AU  - Bundschuh, Ralph A.
AU  - Fendler, Wolfgang P.
AU  - Kurtinecz, Milena
AU  - Schmall, Anja
AU  - Verholen, Frank
AU  - Sartor, Oliver
TI  - Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU Study
AID  - 10.2967/jnumed.122.264456
DP  - 2023 Apr 01
TA  - Journal of Nuclear Medicine
PG  - 574--578
VI  - 64
IP  - 4
4099  - http://jnm.snmjournals.org/content/64/4/574.short
4100  - http://jnm.snmjournals.org/content/64/4/574.full
SO  - J Nucl Med2023 Apr 01; 64
AB  - The radium lutetium (RALU) study evaluated the feasibility of sequential α- and β-emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer. Methods: This preplanned interim retrospective analysis investigated safety and survival outcomes with 177Lu-PSMA in patients treated with prior 223Ra. Results: Forty-nine patients were evaluated. Patients received a median of 6 223Ra injections; 59% of patients received at least 4 177Lu-PSMA cycles. Most (69%) patients received at least 4 life-prolonging therapies before 177Lu-PSMA. Common Terminology Criteria for Adverse Events grade 3–4 treatment-emergent adverse events during 177Lu-PSMA therapy and a 30-d follow-up period included anemia (18%) and thrombocytopenia (2%). Median overall survival was 12.6 mo (95% CI, 8.8–16.1 mo) and 31.4 mo (95% CI, 25.7–37.6 mo) from starting 177Lu-PSMA or 223Ra, respectively. Conclusion: 177Lu-PSMA treatment was well tolerated in patients who had received prior 223Ra. 223Ra use before 177Lu-PSMA is feasible and can be considered for future assessment of the optimal treatment sequence.